We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Read MoreHide Full Article
Key Takeaways
Gilead won FDA approval for Bixlenvo, the first STR for suppressed adults unable to take current STRs.
Gilead raised its 2026 HIV sales growth outlook to 9-10%, backed by Biktarvy, Descovy and Yeztugo.
Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities across HIV care.
Gilead Sciences, Inc. (GILD - Free Report) recently won FDA approval for Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed.
The approval makes Bixlenvo the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.
Bixlenvo combines bictegravir, a guideline-recommended integrase strand transfer inhibitor with a high barrier to resistance, and lenacapavir, a first-in-class capsid inhibitor with a novel mechanism of action and no cross-resistance to existing antiretrovirals.
Bixlenvo’s approval strengthens Gilead’s HIV portfolio. The expanded treatment choice could help Gilead address an underserved segment of the HIV market, support patient retention and reinforce its competitive position in HIV treatment.
Gilead’s HIV business continues to gain momentum, led by Biktarvy, Descovy and the rapidly growing Yeztugo. The company raised its 2026 HIV sales growth outlook to 9-10%, supported by a roughly $4 billion annualized PrEP business. Meanwhile, Bixlenvo and the expanding lenacapavir pipeline offer additional growth opportunities, with potential daily, weekly and longer-acting treatments strengthening Gilead’s long-term HIV leadership.
Gilead has a market-leading HIV franchise anchored by flagship therapies, Biktarvy for treatment and Descovy for prevention. The business continues to provide a strong foundation for growth, with Biktarvy maintaining its position as a leading HIV treatment across major markets, while Descovy benefits from continued demand in HIV prevention.
The recent launch of Yeztugo (lenacapavir) provides another important growth opportunity. As the first and only twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) option, Yeztugo offers a significant adherence advantage over daily oral therapies and could expand Gilead’s reach across the growing HIV prevention market. Gilead expects Yeztugo sales to approach $1 billion in 2026, highlighting its potential to become a major contributor to revenues.
Strong performance across the portfolio has already prompted Gilead to raise its 2026 HIV sales growth outlook to 9-10% from 8%. The company’s approximately $4 billion annualized PrEP business, combined with sustained Biktarvy growth, provides a solid base for continued expansion.
Gilead’s pipeline offers additional upside. The approval of Bixlenvo strengthens its treatment portfolio by providing a once-daily single-tablet option for people with HIV looking to switch or simplify therapy. Meanwhile, Gilead and Merck’s (MRK - Free Report) positive phase III results for the once-weekly oral combination of islatravir and lenacapavir could pave the way for another differentiated treatment option.
Gilead’s expanding lenacapavir pipeline could support multiple future growth opportunities across HIV treatment and prevention. Potential once-weekly and longer-acting formulation could help extend the commercial opportunity for lenacapavir well into the next decade.
Competition for GILD’s HIV Business
The HIV treatment landscape is dominated by many bigwigs, such as GSK plc (GSK - Free Report) and Merck, apart from GILD.
HIV sales account for a major chunk of GSK’s Specialty Medicines portfolio. GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. The solid growth from these drugs has helped GSK combat the decline in Triumeq sales.
MRK markets doravirine for treating adults with HIV-1 in the United States, either as a monotherapy under the brand name Pifeltro or as part of the single-tablet combination regimen under the brand name Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).
MRK won FDA approval for Idvynso, a once-daily, two-drug single-tablet regimen containing doravirine (100 mg) and islatravir (0.25 mg), for adults living with HIV-1 who are virologically suppressed on a stable antiretroviral regimen. The approval covers patients with no history of treatment failure and no known resistance-associated mutations to doravirine, allowing them to switch from their current HIV therapy.
GILD’s Price Performance, Valuation and Estimates
Shares of GILD have gained 20.3% year to date compared with the industry’s growth of 8.7%.
Image Source: Zacks Investment Research
Going by the price/earnings ratio, GILD’s shares currently trade at 22.82X forward earnings, higher than its mean of 12.18X and the large-cap pharma industry’s 18.55X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings is pinned at a loss of 49 cents per share. The EPS estimate for 2027 has moved north to $9.88 from $9.68 in the past 60 days.
Image Source: Zacks Investment Research
While Gilead’s recent aggressive dealmaking strategy strengthens its long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.
View the Zacks #1 Rank List
Image: Shutterstock
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Key Takeaways
Gilead Sciences, Inc. (GILD - Free Report) recently won FDA approval for Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed.
The approval makes Bixlenvo the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.
Bixlenvo combines bictegravir, a guideline-recommended integrase strand transfer inhibitor with a high barrier to resistance, and lenacapavir, a first-in-class capsid inhibitor with a novel mechanism of action and no cross-resistance to existing antiretrovirals.
Bixlenvo’s approval strengthens Gilead’s HIV portfolio. The expanded treatment choice could help Gilead address an underserved segment of the HIV market, support patient retention and reinforce its competitive position in HIV treatment.
Gilead’s HIV business continues to gain momentum, led by Biktarvy, Descovy and the rapidly growing Yeztugo. The company raised its 2026 HIV sales growth outlook to 9-10%, supported by a roughly $4 billion annualized PrEP business. Meanwhile, Bixlenvo and the expanding lenacapavir pipeline offer additional growth opportunities, with potential daily, weekly and longer-acting treatments strengthening Gilead’s long-term HIV leadership.
Gilead has a market-leading HIV franchise anchored by flagship therapies, Biktarvy for treatment and Descovy for prevention. The business continues to provide a strong foundation for growth, with Biktarvy maintaining its position as a leading HIV treatment across major markets, while Descovy benefits from continued demand in HIV prevention.
The recent launch of Yeztugo (lenacapavir) provides another important growth opportunity. As the first and only twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) option, Yeztugo offers a significant adherence advantage over daily oral therapies and could expand Gilead’s reach across the growing HIV prevention market. Gilead expects Yeztugo sales to approach $1 billion in 2026, highlighting its potential to become a major contributor to revenues.
Strong performance across the portfolio has already prompted Gilead to raise its 2026 HIV sales growth outlook to 9-10% from 8%. The company’s approximately $4 billion annualized PrEP business, combined with sustained Biktarvy growth, provides a solid base for continued expansion.
Gilead’s pipeline offers additional upside. The approval of Bixlenvo strengthens its treatment portfolio by providing a once-daily single-tablet option for people with HIV looking to switch or simplify therapy. Meanwhile, Gilead and Merck’s (MRK - Free Report) positive phase III results for the once-weekly oral combination of islatravir and lenacapavir could pave the way for another differentiated treatment option.
Gilead’s expanding lenacapavir pipeline could support multiple future growth opportunities across HIV treatment and prevention. Potential once-weekly and longer-acting formulation could help extend the commercial opportunity for lenacapavir well into the next decade.
Competition for GILD’s HIV Business
The HIV treatment landscape is dominated by many bigwigs, such as GSK plc (GSK - Free Report) and Merck, apart from GILD.
HIV sales account for a major chunk of GSK’s Specialty Medicines portfolio. GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. The solid growth from these drugs has helped GSK combat the decline in Triumeq sales.
MRK markets doravirine for treating adults with HIV-1 in the United States, either as a monotherapy under the brand name Pifeltro or as part of the single-tablet combination regimen under the brand name Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).
MRK won FDA approval for Idvynso, a once-daily, two-drug single-tablet regimen containing doravirine (100 mg) and islatravir (0.25 mg), for adults living with HIV-1 who are virologically suppressed on a stable antiretroviral regimen. The approval covers patients with no history of treatment failure and no known resistance-associated mutations to doravirine, allowing them to switch from their current HIV therapy.
GILD’s Price Performance, Valuation and Estimates
Shares of GILD have gained 20.3% year to date compared with the industry’s growth of 8.7%.
Image Source: Zacks Investment Research
Going by the price/earnings ratio, GILD’s shares currently trade at 22.82X forward earnings, higher than its mean of 12.18X and the large-cap pharma industry’s 18.55X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings is pinned at a loss of 49 cents per share. The EPS estimate for 2027 has moved north to $9.88 from $9.68 in the past 60 days.
Image Source: Zacks Investment Research
While Gilead’s recent aggressive dealmaking strategy strengthens its long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.
GILD currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.